Fibroblast growth factor 23 and fibroblast growth factor receptor 4 promote cardiac metabolic remodeling in chronic kidney disease
Kidney International · 2025-05 · 107 (5) · 852-868
DOI: 10.1016/j.kint.2025.01.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney International, 2025-05. Verfasst von Michaela A A Fuchs und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Fibroblast Growth Factors, Myocytes, Cardiac, Hypertrophy, Left Ventricular. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NHLBI NIH HHS, NIBIB NIH HHS.
Abstract (Originalsprache)
Chronic kidney disease (CKD) is a global health epidemic that greatly increases mortality due to cardiovascular disease. Left ventricular hypertrophy (LVH) is an important mechanism of cardiac injury in CKD. High serum levels of fibroblast growth factor (FGF) 23 in patients with CKD may contribute mechanistically to the pathogenesis of LVH by activating FGF receptor (FGFR) 4 signaling in cardiac myocytes. Mitochondrial dysfunction and cardiac metabolic remodeling are early features of cardiac injury that predate development of hypertrophy, but these mechanisms have been insufficiently studied in models of CKD. We found in wild-type mice with CKD induced by adenine diet, that morphological changes occurred in mitochondrial structure and cardiac mitochondrial and that metabolic dysfunction preceded the development of LVH. In bioengineered cardio-bundles and neonatal rat ventricular myocytes grown in vitro, FGF23-mediated activation of FGFR4 caused mitochondrial pathology, characterized by increased bioenergetic stress and increased glycolysis that preceded the development of cellular hypertrophy. The cardiac metabolic changes and associated mitochondrial alterations in mice with CKD were prevented by global and cardiac-specific deletion of FGFR4. Our findings indicate that metabolic remodeling and mitochondrial dysfunction are early cardiac complications of CKD that precede structural remodeling of the heart. Mechanistically, FGF23-mediated activation of FGFR4 causes mitochondrial dysfunction, suggesting that early pharmacologic inhibition of FGFR4 might serve as novel therapeutic intervention to prevent development of LVH and heart failure in patients with CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
- Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA; Department of Biomedical Sciences, University of Veterinary Medicine, Vienna, Austria.
- Department of Biomedical Engineering, Duke University, Durham, North Carolina, USA.
- Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
- Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; German Center for Heart Research (DZHK), Partner Site Hamburg/Lübeck/Kiel, Germany.
- Department of Pathology, Duke University, Durham, North Carolina, USA.
Förderung
- NIH HHS
- NHLBI NIH HHS
- NIBIB NIH HHS
- University of North Carolina
- American Society of Nephrology
- National Institutes of Health
- German Research Foundation
- American Heart Association Inc
Zitieren
APA
Fuchs, M. A. A., Burke, E. J., Latic, N., Murray, S. L., Li, H., Sparks, M. A., Abraham, D., Zhang, H., Rosenberg, P., Saleem, U., Hansen, A., Miller, S. E., Ferreira, D., Hänzelmann, S., Hausmann, F., Huber, T., Erben, R. G., Fisher-Wellman, K., Bursac, N., …, & Grabner, A. (2025). Fibroblast growth factor 23 and fibroblast growth factor receptor 4 promote cardiac metabolic remodeling in chronic kidney disease. Kidney International, 107(5), 852-868. https://doi.org/10.1016/j.kint.2025.01.024
Vancouver
Fuchs MAA, Burke EJ, Latic N, Murray SL, Li H, Sparks MA, et al. Fibroblast growth factor 23 and fibroblast growth factor receptor 4 promote cardiac metabolic remodeling in chronic kidney disease. Kidney International. 2025;107(5):852-868. doi:10.1016/j.kint.2025.01.024
BibTeX
@article{Fuchs2025,
author = {Fuchs, Michaela A A and Burke, Emily J and Latic, Nejla and Murray, Susan L and Li, Hanjun and Sparks, Matthew A and Abraham, Dennis and Zhang, Hengtao and Rosenberg, Paul and Saleem, Umber and Hansen, Arne and Miller, Sara E and Ferreira, Davis and Hänzelmann, Sonja and Hausmann, Fabian and Huber, Tobias and Erben, Reinhold G and Fisher-Wellman, Kelsey and Bursac, Nenad and Wolf, Myles and Grabner, Alexander},
title = {Fibroblast growth factor 23 and fibroblast growth factor receptor 4 promote cardiac metabolic remodeling in chronic kidney disease},
journal = {Kidney International},
year = {2025},
volume = {107},
number = {5},
pages = {852--868},
doi = {10.1016/j.kint.2025.01.024}
}
EUVIMED